Core Viewpoint - Hims & Hers has abandoned its plan to offer a compounded version of the weight-loss drug Wegovy, following threats from the FDA and legal action from Novo Nordisk, the original manufacturer of Wegovy [1][1][1] Company Actions - Hims & Hers announced the decision to drop the compounded semaglutide pill just two days after its introduction, citing constructive conversations with industry stakeholders [1][1] - The company had initially planned to sell its version of Wegovy at a significantly lower price of $49 for the first month and $99 thereafter, compared to Novo's price of $149 per month [1][1][1] Regulatory Environment - The FDA indicated plans to restrict access to the active ingredients necessary for compounding popular GLP-1 drugs, which include Wegovy, Ozempic, and Zepbound [1][1] - The FDA has stated that GLP-1 drugs are no longer in shortage as of 2024, which is expected to end the practice of compounding these medications [1][1] Market Context - Hims & Hers, along with other companies, entered the multibillion-dollar market for obesity medications, driven by the high demand for GLP-1 drugs [1][1] - The compounded version of the semaglutide pill that Hims planned to sell was not FDA-approved and had not undergone trials to prove its effectiveness [1][1]

Hims & Hers Stock Plunges 24%. Its Weight-Loss Drug Strategy Backfired. - Barron'sSkip to Main ContentThis copy is for your personal, non-commercial use only. Distribution and use of this material are governed by our Subscriber Agreement and by copyright law. For non-personal use or to order multiple copies, please contact Dow Jones Reprints at 1-800-843-0008 or visit www.djreprints.com.# Hims & Hers Stock Plunges 24%. Its Weight-Loss Drug Strategy Backfired.By [George Glover]ShareResize---ReprintsIn this a ...

来源：滚动播报 诺和诺德股价回吐部分涨幅，最新涨 5.2%。 ...

Group 1 - The FDA has deemed a television advertisement for Novo Nordisk's weight loss pill as "false or misleading" [1] - The communication from the FDA was documented in a letter dated February 5 [1]

Core Insights - Novo Nordisk's shares faced significant pressure due to a disappointing 2026 outlook, overshadowing a strong fourth-quarter performance [1] - Hims & Hers Health's announcement to launch a compounded oral semaglutide pill intensified competition in the weight-loss market, posing a threat to Novo Nordisk's flagship product, Wegovy [2][3] - The FDA's intervention against non-FDA-approved compounded GLP-1 drugs provided a temporary relief for Novo Nordisk's stock, which rebounded sharply [6] Company Performance - Novo Nordisk's stock has declined by 4.5% over the past six months, underperforming the industry growth of 34.5% [11] - The company's shares are trading at a price/earnings ratio of 14.31, lower than the industry average of 18.76 and significantly below its five-year mean of 29.25 [14] Market Dynamics - The obesity treatment market is becoming increasingly competitive, with Eli Lilly also advancing its GLP-1-based drugs and seeking approval for an oral GLP-1 pill [8] - The introduction of lower-priced alternatives, such as Hims' $49 compounded pill, raises concerns about pricing power and demand for Novo Nordisk's products [4][9] Regulatory Environment - The FDA has issued warnings against misleading marketing of compounded GLP-1 drugs, which could impact companies like Hims & Hers Health [6] - Novo Nordisk has indicated potential legal actions to protect its intellectual property and patient safety in response to the competitive threat [5] Earnings Estimates - Earnings estimates for Novo Nordisk have declined, with 2026 estimates dropping from $3.55 to $3.32 per share and 2027 estimates from $3.65 to $3.39 [17]

Group 1 - The U.S. stock market showed mixed results, with major indices fluctuating and most Chinese concept stocks declining [1] - Nvidia experienced a significant intraday surge, rising over 4%, with Goldman Sachs analysts projecting Q4 2025 revenue to reach $67.3 billion, exceeding market expectations [3] - Oracle's stock surged nearly 9.6%, marking its largest intraday gain since December of the previous year, following an upgrade from Davidson Investment Bank from "neutral" to "buy" [3] Group 2 - Storage stocks weakened, with Micron Technology falling nearly 2.5% and SanDisk dropping over 1.4%, as Nvidia may exclude Micron's HBM4 from the first-year production of its Rubin architecture [5] - The weight loss drug sector saw gains, with Novo Nordisk rising over 5% and Eli Lilly increasing nearly 1%, while Hims & Hers plummeted over 25% due to a lawsuit related to a generic version of semaglutide [5] - The gold and silver markets rebounded significantly, with spot gold rising over 1.4% to nearly $5,040 per ounce and spot silver increasing over 5% to $81.696 per ounce [5][6] Group 3 - International oil prices saw a short-term rise, with WTI crude oil and ICE Brent crude both increasing by 1%, and WTI crude surpassing $64 per barrel [6] - Upcoming U.S. non-farm payroll and CPI reports are expected to provide crucial insights into the Federal Reserve's monetary policy direction, with potential for significant market volatility if the data indicates "weak employment + stubborn inflation" [7] Group 4 - The UK faced a "triple whammy" in its stock, bond, and currency markets, with the FTSE 100 index and GBP/EUR exchange rate both plummeting, and the 10-year government bond yield approaching its highest point since November of the previous year [9] - The resignation of two senior officials from the UK Prime Minister's office within 24 hours has raised concerns about political stability, which may impact market confidence [9]

| Hims & Hers Health Inc-A (Ai) [ Q | | | --- | --- | | HIMS | | | 16.350 16.923 >> | 17.825 最高 17.900 最低 | | 3.25亿 -26.49% -6.097 快手 | 8.05% 总量 1833万股 金额 | | 盘前 09:30 美东 V | 17.830 -5.190 -22.55% | | 国 年报预披露: 于2026-02-23(美东)盘后披露2025财年年报 ( ... ● | | | 均价:17.712 最新:16.923 -6.097 -26.49% | | | 29.561 | | | 300 9:36 16.950 | | | 9:36 16.950 141 | | | 23.020 - 9:36 16.9601 100 | | | 9:36 16.960 100 | | | 9:36 16.960 125 | | | 100 9:36 16.9234 | | | 9:36 16.940↑ 100 | | | 9:36 16.960↑ 500 | | | -28.42% 9:36 16.9 ...

Let's begin with Novo Nordisk suing hims and hers, accusing the telehealth firm of infringing its U.S. patent on key ingredient in its epic. And we go by. Let's get the latest.The same for he's the senior pharmaceutical analyst at Bloomberg Intelligence. Sam, we were just talking on Friday and you were telling us there is a danger to this. This isn't good.It sounds like hims and hers has finally listened to some of the criticism and threats coming from regulators. Yeah, well, Daddy, the point here is not ab ...

Novo Nordisk A/S (NYSE:NVO) on Monday said it has filed a lawsuit against telehealth company Hims & Hers Inc. (NYSE:HIMS) for infringing U.S. Patent 8,129,343 with Hims’ compounded semaglutide products for the U.S. market.Novo Nordisk’s Legal Move ExplainedNovo Nordisk, in its press release, said Hims & Hers engaged in promotional campaigns that highlight its compounded semaglutide products, duping consumers and healthcare professionals as to the clinical benefits and safety of these unapproved drugs.Hims c ...

Market Overview - US stocks experienced a positive turn on Monday, with the S&P 500 rising approximately 0.5% and the Nasdaq Composite gaining nearly 1%, while the Dow Jones Industrial Average remained above 50,000 for the first time [1] - Wall Street is currently debating the impact of AI disruptions on software companies, highlighted by a significant drop in shares of Monday.com, which fell as much as 22% due to disappointing revenue and profit guidance [2][12] Company Earnings and Performance - Cleveland-Cliffs stock dropped 19% after the steel producer's fourth-quarter revenue of $4.3 billion fell short of estimates of $4.5 billion, with a net loss per share of $0.44, which was better than the expected loss of $0.60 [5][6][7] - Monday.com reported adjusted earnings per share of $1.04, exceeding estimates of $0.92, but its first-quarter revenue guidance of $338 million to $340 million was below expectations of $342 million, leading to a 15% drop in stock price [19][20][21] - Kroger's stock surged over 8% after announcing the appointment of former Walmart executive Greg Foran as CEO, aiming to capture market share following a blocked acquisition [9][10] Economic Data and Trends - Investors are awaiting the delayed January jobs report from the Bureau of Labor Statistics, with a focus on potential signs of weakness in the labor market following a disappointing ADP payroll update [4] - Gold futures rose above $5,000 an ounce, while Bitcoin fell below $69,000 after experiencing significant volatility [3][26][27] Strategic Developments - STMicroelectronics announced a multiyear, multibillion-dollar deal with Amazon to supply chips for its data centers, resulting in an 8% increase in STMicroelectronics' stock [13][14][15] - QuantumScape's stock rose 14% following the launch of its "Eagle Line" battery production factory in San Jose [28]